

Immuron shares are surging Friday after it announced an exclusive deal with Calmino group AB to launch PROIBS gut health product in the U.S.
You can purchase shares of Immuron (NASDAQ:IMRN) through any online brokerage.
Other companies in Immuron’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Immuron has a consensus price target of $5.00.
The stock price for Immuron (NASDAQ: IMRN) is $0.92 last updated November 11, 2026 at 6:10 PM EST.
There are no upcoming dividends for Immuron.
Immuron does not have any upcoming earnings scheduled.
There is no upcoming split for Immuron.
Immuron is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Immuron Ltd is a commercial- and clinical-stage biopharmaceutical company focused on the development and commercialization of specifically targeted polyclonal antibodies. Its oral polyclonal antibodies offer delivery within the GI tract and can...